Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Company News for Oct 28, 2020
by Zacks Equity Research
Companies In The News Are: PFE, LLY, MMM, SHW.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Exelixis' (EXEL) Applications for Cabometyx-Opdivo Combo Accepted (Revised)
by Zacks Equity Research
Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.
Lilly (LLY) Q3 Earnings & Revenues Lag Estimates, Stock Down
by Zacks Equity Research
Eli Lilly (LLY) misses on both earnings and sales for the third quarter. The company reiterates its revenue guidance for 2020.
The Zacks Analyst Blog Highlights: Pfizer, Merck & Co., Bristol-Myers Squibb and Amgen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Merck & Co., Bristol-Myers Squibb and Amgen
Pfizer (PFE) Q3 Earnings Top, Sales Miss, View Narrowed
by Zacks Equity Research
Pfizer (PFE) beats estimates for earnings while missing the same for sales. It narrows its financial outlook for the year.
Pfizer (PFE) Q3 Earnings Beat Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 2.86% and -0.83%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Pfizer's (PFE) Oncology Drugs Drive Its Q3 Earnings?
by Zacks Equity Research
In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the third quarter, while in non-oncology, Eliquis alliance revenues are likely to have supported the top line.
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
Novartis (NVS) Gets Orphan Drug Tag for Huntington's Disease Drug
by Zacks Equity Research
Novartis (NVS) gets orphan drug designation for branaplam (LMI070) in Huntington's disease.
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Pharmaceutical and Consumer Healthcare segments are likely to have driven third-quarter sales. Results will provide clarity on the impact of coronavirus on the company's vaccine business.
AstraZeneca (AZN), J&J (JNJ) Coronavirus Trials May Resume Soon
by Zacks Equity Research
Clinical studies on coronavirus vaccine candidates of AstraZeneca (AZN) and J&J (JNJ) which were paused for reviewing adverse events are anticipated to resume as early as this week.
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
Merck (MRK) Pneumococcal Vaccine Meets Late-Stage Study Goals
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.
Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline
by Zacks Equity Research
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis' (EXEL) Cabometyx Combo Approved by FDA for RCC
by Zacks Equity Research
Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.
Aptinyx (APTX) Surges on Promising Stress Disorder Study Data
by Zacks Equity Research
Aptinyx (APTX) is developing a NMDA receptor-targeted candidate, NYX-783, as potential treatment for post-traumatic stress disorder.
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, in the Biopharma segment are likely to have made up for lower sales in the Upjohn group in the third quarter.
Pfizer (PFE) Stock Moves -0.4%: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $37.80 in the latest trading session, marking a -0.4% move from the prior day.
Weekly ETF Roundup: Broad U.S. Equity Tops, Biotech Flops
by Sweta Killa
ETFs overall gathered about $18.5 billion capital last week, bringing year-to-date inflows of $352.6 billion, ahead of the $211.7 billion seen at this same time a year ago.
Stock Market News for Oct 19, 2020
by Zacks Equity Research
The Dow and the S&P 500 closed higher on Friday, lifted by upbeat retail sales data and improvement in consumer sentiment.
Lilly to Acquire Private Biotech for Boosting Pain Portfolio
by Zacks Equity Research
Lilly (LLY) inks a deal to acquire Disarm Therapeutics for an upfront payment of $135 million to strengthen its pain and neurological diseases portfolio.
Retail and Core Retail Sales Jump in September
by Zacks Equity Research
Retail and Core Retail Sales Jump in September.
Retail Sales +1.9%, Industrial Production -0.6%
by Mark Vickery
While September Retail Sales were ahead of expectations, Industrial Production last month was decidedly not.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, Target, Prudential Financial and Seagate Technology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, Target, Prudential Financial and Seagate Technology